{"id":34290,"date":"2025-12-23T17:34:35","date_gmt":"2025-12-23T16:34:35","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&p=34290"},"modified":"2026-04-12T12:06:15","modified_gmt":"2026-04-12T10:06:15","slug":"slu-pp-332","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/shop-product\/slu-pp-332\/","title":{"rendered":"SLU-PP-332 500 mcg 60 caps"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

SLU-PP-332 - what it is and how it works<\/strong><\/h2>

SLU-PP-332 is experimental estrogen-related receptors (ERR) agonist<\/strong> - A group of nucleolar nuclear receptors involved in the regulation of Energy metabolism, mitochondrial function and fat consumption<\/strong>. The substance is classified as \u201eexercise mimetic\u201d<\/strong>, a pharmacological compound that, in preclinical models, activates similar metabolic pathways as intense physical activity, leading to Increased expression of genes related to fatty acid oxidation, mitochondrial biogenesis and muscle endurance capacity<\/strong>.\u00a0<\/p>

Mechanistically, the SLU-PP-332 works by. Binding to ERR\u03b1, ERR\u03b2 and ERR\u03b3 receptors<\/strong>, with the highest activity toward ERR\u03b1, which stimulates intracellular pathways regulating mitochondrial metabolism and the expression of genes related to aerobic muscle adaptation. In activated ERRs, there is an increase in the expression of proteins involved in oxidative phosphorylation, fat beta-oxidation and glucose transport<\/strong>, which resembles the metabolic adaptations observed after intense exercise.<\/p>

Also check out Tesofensine 500mcg\/30caps<\/a><\/p>

SLU PP 332 vs. weight loss<\/h2>

Based on available preclinical studies, SLU-PP-332 has not been directly developed as a classical weight-reduction agent, but its mechanism of action suggests indirect potential to influence the body's energy balance<\/strong>. By activating ERR receptors and enhancing metabolic pathways related to mitochondrial function and fatty acid oxidation, the compound leads to increased energy expenditure in muscle tissue<\/strong>.<\/p>

In animal models, improvements in metabolic parameters, increased energy consumption, and changes in muscle fiber profile toward a more aerobic phenotype have been observed, which promotes a better use of energy substrates<\/strong>, including lipids. Such metabolic adaptations can experimentally reduce obesity-promoting metabolic disorders and indirectly affect weight control.<\/p>

However, it should be emphasized that Weight loss was not the primary endpoint of the SLU-PP-332 study<\/strong>, and all observations are in preclinical models only. The lack of clinical data makes it impossible to assess the efficacy and safety of the compound in the context of weight reduction in humans, so the potential effect of SLU-PP-332 on weight loss remains at the stage of research hypotheses and requires further clinical studies.<\/p>

SLU-PP-332 - study status and dosage.<\/strong><\/h2>

SLU-PP-332 remains at preclinical research stage<\/strong>. No human clinical trials have been conducted, and dosage information relates only to animal models, mainly mice. The compound has no approved therapeutic guidelines or clinical dosage in humans.<\/p>

Various dosage regimens have been used in preclinical models, most commonly from 30 mg\/kg to 50 mg\/kg<\/strong> orally to study metabolic effects, muscle adaptations and \u201eexercise mimetic action\u201d<\/strong>.<\/p>

SLU-PP-332 - metabolic and \u201eexercise mimetic\u201d effects\u201d<\/strong><\/h2>

Preclinical studies have shown that SLU-PP-332 activates the A genetic program similar to that induced by aerobic training<\/strong>, which results in:<\/p>